Article

Customized LASIK provides measurable clinical and economic benefits

Lisbon, Portugal - A shift from conventional to wavefront-guided LASIK has resulted in reduced enhancement rates that translate into significant cost savings to the practice, said Richard L. Lindstrom, MD, adjunct professor emeritus, department of ophthalmology, University of Minnesota, and founding partner, Minnesota Eye Consultants, Minneapolis, United States.

Lisbon, Portugal - A shift from conventional to wavefront-guided LASIK has resulted in reduced enhancement rates that translate into significant cost savings to the practice, said Richard L. Lindstrom, MD, adjunct professor emeritus, department of ophthalmology, University of Minnesota, and founding partner, Minnesota Eye Consultants, Minneapolis, United States.

To evaluate the clinical and economic impact of wavefront-guided LASIK at Minnesota Eye Consultants, Dr. Lindstrom performed a retrospective study evaluating outcomes for two cohorts of patients treated over a 12-month period. The first group underwent conventional LASIK with a VISX laser between August 2001 and July 2002, and the second group was treated with customized LASIK using the VISX CustomVue system from August 2003 to July 2004. All patients treated during each period were included, and enhancement rates were calculated based on procedures performed during the 13-month period after the primary surgery.

For the conventional LASIK group, 62% of eyes achieved uncorrected visual acuity (UCVA) of 20/20 or better and the enhancement rate was 9.8%. With customized ablation, 91% of eyes achieved UCVA of 20/20 or better and the enhancement rate was cut nearly in half to 5.2%. Dr. Lindstrom estimated the reduced need for enhancement resulted in an approximate $100,000 savings for the practice.

“We believe there are many ways to reduce the enhancement rate still further. However, the enhancement rate for a more contemporary group of patients is probably even lower than 5.2% taking into account the current availability of customized treatment for patients with hyperopia, mixed astigmatism, and higher levels of myopia. Based on our experience, we have now become a 100% custom practice and perform the CustomVue procedure for any patient who is qualified for it,” said Dr. Lindstrom. He is a consultant to VISX.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.